The short version
- Why people research itSoft-tissue and gut repair, reduced inflammation, angiogenesis and faster recovery from injury.
- What the evidence isTeduglutide — a GLP-2 analog — is FDA-approved for short bowel syndrome, on randomized trials showing reduced parenteral nutrition requirement.
- What to watchBlack or bloody stools.
How GLP-2 works
Intestinal growth factor — drives gut mucosal growth and reduces permeability; the analog teduglutide treats short-bowel syndrome.
The single most important fact about GLP-2 is that its receptor is not on the cell it grows. Orskov 2005 localized the GLP-2 receptor, by immunohistochemistry and in situ hybridization, mainly to subepithelial myofibroblasts in the small and large intestine of rat, mouse, marmoset and human.
Read what that means. GLP-2 does not tell an enterocyte to divide. It tells a myofibroblast sitting underneath the epithelium to release a growth factor, and the growth factor tells the crypt.
- Injectable
On the goal map: Gut lining & mucosal repair (Heal an injury)
Where to get GLP-2
When a vetted partner does, the link and code go here.
Research on GLP-25 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: FDA-approved (teduglutide).
Human clinical evidence
Teduglutide — a GLP-2 analog — is FDA-approved for short bowel syndrome, on randomized trials showing reduced parenteral nutrition requirement. That is a hard, meaningful endpoint.
Native GLP-2 itself has human PK data but no approval, since its half-life is minutes.
Correlative data
Community use for intestinal permeability and gut repair. The approved analog's evidence is in a severe surgical population, and how much transfers to someone with ordinary gut complaints is entirely unstudied.
How the mechanism reads
An intestinotrophic hormone released alongside GLP-1 — it increases villus height, crypt depth and mucosal blood flow, and reduces intestinal permeability.
MechanisticThe proliferative mechanism is also the caution. Teduglutide's label carries a colorectal polyp warning and requires colonoscopic surveillance, because a hormone whose job is to grow intestinal mucosa does not distinguish welcome growth from unwelcome.
Mechanistic
Sources
- Hartmann B. In vivo and in vitro degradation of glucagon-like peptide-2 in humans.. J Clin Endocrinol Metab 2000 · PMID 10946898
- Drucker DJ. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV.. Nat Biotechnol 1997 · PMID 9219272
- Orskov C. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors.. Regul Pept 2005 · PMID 15544847
- Guan X. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow.. Gastroenterology 2006 · PMID 16401478
- US Food and Drug Administration. GATTEX (teduglutide) for injection - full prescribing information.. FDA approved labeling, revision 2019
GLP-2 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Past or current gut polyps or gastrointestinal cancer, because mucosal growth is its action.
- Active intestinal obstruction.
- Heart failure or fluid overload, as it increases absorbed fluid.
- Gallbladder or pancreatic disease.
- Pregnancy, since gut growth peptides have no reproductive safety data.
What’s expected
- Growth of the intestinal lining and better absorption.
- Bloating, abdominal fullness and fluid retention.
- Reduced gut permeability, mediated by KGF release from subepithelial cells.
Watch for
- Black or bloody stools.
- Vomiting with a swollen belly, a possible obstruction.
- Right upper abdominal pain, from gallbladder or biliary change.
Labs that tell you it’s working
- CEA (Carcinoembryonic Antigen): a colon-tumor marker, relevant to a drug that accelerates mucosal growth.
- Ferritin: slow gut bleeding appears as falling iron stores.
- Amylase: a pancreatic enzyme if upper belly pain appears.
- Comprehensive Metabolic Panel: fluid, electrolyte and liver status.
Intestinal growth hormone (GLP-2); teduglutide's label warns of accelerated neoplastic growth because mucosal proliferation is the mechanism. PMID 15544847
Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
GLP-2 FAQ4 common questions
- Is GLP-2 approved for human use?
- GLP-2 is an approved medicine for the uses on its label. This page covers research beyond those uses, as education, not medical advice.
- What is GLP-2 researched for?
- Soft-tissue and gut repair, reduced inflammation, angiogenesis and faster recovery from injury.
- Which labs show whether it's doing anything?
- CEA; Ferritin; Amylase; Comprehensive Metabolic Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for GLP-2: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



